Page 4 - Board Certification News Today

The severity of TRD appeared to predict response to IV ketamine vs ECT. However, experts said more research is needed before drawing any definitive conclusions.

An analysis evaluated growth in a study of 1326 children with AD younger than 12 years.

Expect intradermal injections of botulinum toxin A for the improvement in the appearance of pores, sebum, skin texture, and rosacea to gain a foothold in dermatology practices, one expert says.

New data supported the safety and efficacy of nonmedical switching from infliximab to a biosimilar, according to researchers.

Sonelokimab is a novel humanized nanobody that selectively binds to interleukin (IL)-17A and IL-17F.

Treatment with the topical JAK inhibitor reduced abscess and inflammatory nodules in a phase 2 randomized, controlled trial in patients with mild hidradenitis suppurativa.

Lawsuit claimed Seattle-area eye surgery practice engaged in gender discrimination and workplace retaliation.

Eli Lilly and Company, which manufactures one of the new weight-loss drugs, has launched an advertising campaign reinforcing that the drugs should not be used for cosmetic weight loss.

A recent study evaluated the association between sarcopenia and sarcopenic obesity with mortality risk.

Despite the revised figures, Black women continue to experience pregnancy-related deaths far more than other groups, researchers said.